Investigators compared the clinical characteristics of patients who developed both DE and NOP after LASIK to those with only DE and to asymptomatic LASIK patients.
News
Researchers conducted a systematic review and meta-analysis to evaluate the association between smoking and primary headache.
Atogepant is an oral calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults.
Researchers investigated the efficacy of 2 different ocular lubricants on dry eye disease, migraine severity, and ocular symptoms.
Investigators examined GLP-1 RAs as a potential promising approach to alleviating migraine in a pilot prospective observational study.
Researchers conducted a prospective study involving 31 patients who underwent MRI to examine the effectiveness of delayed postgadolinium 3-dimensional sampling perfection with application-optimized contrasts using different flip angle evolution fluid-attenuated inversion recovery sequence to differentiate between MD and VM.
In a retrospective review, researchers assessed the effect of galcanezumab exposure during pregnancy on maternal and fetal outcomes and compared these outcomes to those seen with placebo.
In a single-center, randomized, staggered-start, open-label clinical trial, researchers evaluated rimegepant for short-term prevention of fasting-related headache in adults fasting during Ramadan.
In a network meta-analysis of data from the CHALLENGE-MIG trial, researchers evaluated the relative efficacy and safety of atogepant compared with rimegepant and galcanezumab for the preventive treatment of episodic migraine.
In a small retrospective review, researchers assessed safety and efficacy of CGRP-targeted vs propranolol/metoprolol therapies in patients with both dysautonomia and headache disorders.
In a post hoc analysis, researchers examined the association between atogepant use and weight loss in patients with overweight or obesity receiving treatment for episodic or chronic migraine.
Using data from the ASCEND trial, researchers determined the effect of STS101 on cardinal symptoms of migraine.
In a post hoc REVIEW study analysis, researchers compared self-reported outcomes by level of improvement in good days/month with eptinezumab.
In the phase 3 EMERGE trial, researchers evaluated the efficacy and safety of meloxicam and rizatriptan in patients with migraine undergoing treatment with gepant for less than a month and experiencing an inadequate response.
In a post hoc subgroup analysis of a phase 3 randomized, double-blind, sham-controlled clinical trial, researchers examined whether patients with migraine with vs without aura respond differently to a 2-hour eTNS treatment, using data from the TEAM study.
In a retrospective chart review, researchers assessed the prevalence of normal vs abnormal brain MRI findings in pediatric patients diagnosed with migraine.
In a retrospective analysis, researchers assessed the effect of CoQ10 supplementation in pediatric patients diagnosed with new daily persistent headache.
In a phase 3, randomized, double-blind, placebo-controlled study, researchers assessed the safety and efficacy of fremanezumab for the prevention of headaches due to migraine in children and adolescents with episodic migraine.
In a double-blind, randomly assigned clinical trial, researchers evaluated the safety and efficacy of fremanezumab in adults with migraine and major depressive disorder.
Xifyrm alone is not recommended for use when rapid onset of analgesia is required.
Researchers assessed the real-world effectiveness and tolerability of erenumab and its impact on quality of life and disability in patients with episodic and chronic migraine.
Researchers evaluated the association between migraine and risk for postpartum depression and whether certain comorbidities could impact this risk.
Brekiya consists of dihydroergotamine mesylate, an ergotamine derivative, in a single-dose autoinjector for subcutaneous administration.
Atzumi is a drug-device combination consisting of dihydroergotamine, an ergotamine derivative.
Researchers assessed patient values and preferences regarding outcomes and attributes of pharmacologic treatment for acute episodic migraine.
In a systematic review and meta-analysis, researchers examined the association between allergic diseases and migraine risk.
In a prospective cohort study, researchers evaluated the effects of spinal cord stimulation in the treatment of painful diabetic peripheral neuropathy.
Investigators enrolled 104 MD patients to examine the relation of MD and migraine.
Researchers sought to examine the relationship between chronotype, physical and mental health, and headache characteristics in patients with and without migraine.
Investigators conducted a phase 3, placebo-controlled trial to examine whether ubrogepant 100 mg dosed during the premonitory (prodromal) phase of migraine prevented headache development and resolved prodromal symptoms.
